Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study

CONCLUSION: Our findings suggest little to no increased risk of cardiovascular and cerebrovascular events in patients treated with LDX compared with patients previously treated with other ADHD medications.

via https://pubmed.ncbi.nlm.nih.gov/36028603/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=None&utm_content=1HYeX0emtvYgH07Wkz0a8n9otrdMd-JIklc_uo0I5vh1u9WMEy&fc=None&ff=20220828010805&v=2.17.7